\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ follow\\-up\\ mri\\ three\\ weeks\\ later\\ revealed\\ subtotal\\ resolution\\ of\\ many\\ of\\ the\\ lesions\\.\\ this\\ is\\ consistent\\ with\\ the\\ monophasic\\ illness\\ of\\ most\\ patients\\ with\\ adem\\.\ \(0\)\
\-\ multiple\\ enhancing\\ brain\\ lesions\\ with\\ increased\\ t2\\ signal\\ intensity\\.\\ lesions\\ involve\\ cerebral\\ white\\ matter\\,\\ gray\\ matter\\,\\ and\\ cerebellum\\.\\ no\\ mass\\ effect\\.\\ no\\ restricted\\ diffusion\\.\\ minimal\\ enhancement\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ infarcts\ \(0\)\
\-\ \\â\\€\\¢\\ sickle\\ cell\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ adem\\ \\(acute\\ disseminated\\ encephalo\\-myelitis\\)\ \(0\)\
\-\ 4\\ y\\.o\\.\\ girl\\ presents\\ with\\ lethargy\\ and\\ possible\\ seizure\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ disseminated\\:\\ 0\\.11314348937657116\ \(0\)\
\-\ adem\\:\\ 0\\.11199906038775764\ \(0\)\
\-\ encephalo\\-myelitis\\:\\ 0\\.09582085243441846\ \(0\)\
\-\ monophasic\\:\\ 0\\.07634520602976567\ \(0\)\
\-\ lesions\\:\\ 0\\.07459436433730264\ \(0\)\
\-\ matter\\:\\ 0\\.07314086892175647\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.0681310587650386\ \(0\)\
\-\ subtotal\\:\\ 0\\.06794096811418436\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.06222256489791502\ \(0\)\
\-\ multiple\\:\\ 0\\.05868932620041094\ \(0\)\
\-\ lethargy\\:\\ 0\\.05849490455957991\ \(0\)\
\-\ illness\\:\\ 0\\.05168560231978347\ \(0\)\
\-\ sickle\\:\\ 0\\.05131710719287389\ \(0\)\
\-\ infarcts\\:\\ 0\\.049956638247721646\ \(0\)\
\-\ cerebellum\\:\\ 0\\.046208372092376764\ \(0\)\
\-\ acute\\:\\ 0\\.04586694193709772\ \(0\)\
\-\ gray\\:\\ 0\\.045443363431922415\ \(0\)\
\-\ involve\\:\\ 0\\.043782898708526655\ \(0\)\
\-\ restricted\\:\\ 0\\.04274691849326225\ \(0\)\
\-\ diffusion\\:\\ 0\\.041577019969432194\ \(0\)\
\-\ seizure\\:\\ 0\\.041071367625574666\ \(0\)\
\-\ resolution\\:\\ 0\\.04006108379395027\ \(0\)\
\-\ many\\:\\ 0\\.03817623386855894\ \(0\)\
\-\ minimal\\:\\ 0\\.03657043446087824\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.03430474139355301\ \(0\)\
\-\ intensity\\:\\ 0\\.03357250735194892\ \(0\)\
\-\ later\\:\\ 0\\.03353715914122743\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03336212210246027\ \(0\)\
\-\ effect\\:\\ 0\\.03288650275075266\ \(0\)\
\-\ girl\\:\\ 0\\.03265627642380215\ \(0\)\
\-\ cerebral\\:\\ 0\\.03217876632352251\ \(0\)\
\-\ three\\:\\ 0\\.03131113291681424\ \(0\)\
\-\ possible\\:\\ 0\\.031282415422652955\ \(0\)\
\-\ white\\:\\ 0\\.030805480572956713\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.030217793385236325\ \(0\)\
\-\ revealed\\:\\ 0\\.029809498802892315\ \(0\)\
\-\ enhancing\\:\\ 0\\.02912992970526912\ \(0\)\
\-\ brain\\:\\ 0\\.027949473079377847\ \(0\)\
\-\ y\\.o\\:\\ 0\\.026808472093333695\ \(0\)\
\-\ weeks\\:\\ 0\\.026361714748925524\ \(0\)\
\-\ t2\\:\\ 0\\.026289008355982087\ \(0\)\
\-\ 4\\:\\ 0\\.025880129404120055\ \(0\)\
\-\ cell\\:\\ 0\\.025089572951972675\ \(0\)\
\-\ enhancement\\:\\ 0\\.024896617023076478\ \(0\)\
\-\ signal\\:\\ 0\\.024489938372530204\ \(0\)\
\-\ patients\\:\\ 0\\.024038854340935063\ \(0\)\
\-\ consistent\\:\\ 0\\.02277498118294786\ \(0\)\
\-\ increased\\:\\ 0\\.022722660671735388\ \(0\)\
\-\ most\\:\\ 0\\.021443860236174738\ \(0\)\
\-\ mri\\:\\ 0\\.02133995494472413\ \(0\)\
\-\ presents\\:\\ 0\\.0189743945163905\ \(0\)\
\-\ no\\:\\ 0\\.018705307623995696\ \(0\)\
\-\ disease\\:\\ 0\\.015181929795822871\ \(0\)\
\-\ mass\\:\\ 0\\.012918054423343091\ \(0\)\
\-\ this\\:\\ 0\\.010447143622979707\ \(0\)\
\-\ \\(\\:\\ 0\\.007851757893955005\ \(0\)\
\-\ \\)\\:\\ 0\\.007755844479492446\ \(0\)\
\-\ is\\:\\ 0\\.006111856286790496\ \(0\)\
\-\ \\,\\:\\ 0\\.005885001424288856\ \(0\)\
\-\ with\\:\\ 0\\.005087138090864771\ \(0\)\
\-\ and\\:\\ 0\\.003913239255048227\ \(0\)\
\-\ of\\:\\ 0\\.0037990369825431007\ \(0\)\
\-\ \\.\\:\\ 0\\.003472780705175179\ \(0\)\
\-\ the\\:\\ 0\\.0030054192326875173\ \(0\)\
